Explore studies of dosing.
Bremelanotide significantly improved desire and reduced HSDD-related distress in Phase 2/3 trials, with nausea (39.9%), flushing (20.4%), and headache (11%) as main side effects.
Mayer, Danielle; Lynch, Sarah E · Review
PTH's dual bone-building and bone-resorbing effects depend on administration pattern, working through Wnt, cAMP, and RANKL pathways. PTH-related peptides in development may overcome teriparatide's clinical limitations.
Chen, Tianhong; Wang, Yi; Hao, Zhuowen; Hu, Yingkun; Li, Jingfeng · Review
Combining GLP-1 RA and DPP-4 inhibitor provides only a small incremental reduction in HbA1c and weight loss, with the benefit unlikely to offset potential pancreatitis risk and additional cost.
Cowart, Kevin; Updike, Wendy H; Lloyd, Andie; Bullers, Krystal · Systematic Review
Compared to tirzepatide 5 mg: - 10 mg: additional 19% HbA1c reduction (MD: -0.19), additional 1.96 kg weight loss - 15 mg: additional 31% HbA1c reduction (MD: -0.32), additional 3.31 kg weight loss, and improved fasting glucose (MD: -6.71 mg/dL) The dose-response relationship was clear and consistent across the 10 studies. Higher doses produced incrementally better metabolic outcomes. For safety, gastrointestinal events were numerically higher with increasing doses but without reaching statistical significance. There were no significant differences across doses for death, nausea, diarrhea, vomiting, dyspepsia, decreased appetite, injection site reactions, hypoglycemia, treatment discontinuation, or serious adverse events.
Rangwala, Hussain Sohail; Fatima, Hareer; Ali, Mirha; Mustafa, Muhammad Saqlain; Shafique, Muhammad Ashir; Rangwala, Burhanuddin Sohail; Abbas, Syed Raza · Network Meta Analysis
Dose escalation from 7 mg to 14 mg oral semaglutide produced a significant additional HbA1c reduction of -0.5 ± 0.8% (from 7.4% to 7.0%, p<0.01) and weight loss of -2.0 ± 4.4 kg (p<0.01) over 24 weeks. 41% of patients achieved ≥3% weight reduction. GI disorders occurred in 10.6% (nausea 7.6%), all mild-moderate.
Sato, Genki; Uchino, Hiroshi; Hirose, Takahisa · Cohort
Hydrogel microsphere-semaglutide showed an in vivo release half-life of ~36 days in mice. A single subcutaneous dose produced 20% lean-sparing body weight loss over one month, statistically equivalent to twice-daily semaglutide. Pharmacokinetic simulations predicted once-monthly human dosing with Cmin matching weekly dosing but only 75% of the Cmax, potentially reducing adverse effects.
Schneider, Eric L; Hangasky, John A; Fernández, Rocío Del Valle; Ashley, Gary W; Santi, Daniel V · Animal Study